Skip to product information
1 of 1

Mouse Anti-Human CD172a (SIRPα) Antibody (S-4039)

Mouse Anti-Human CD172a (SIRPα) Antibody (S-4039)

Catalog Number: S0B8519 Application: FCM Reactivity: Human Conjugation: Unconjugated Brand: Starter
Price:
Regular price $100 USD
Regular price Sale price $100 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Mouse
Antigen CD172a (SIRPα)
Synonyms Tyrosine-protein phosphatase non-receptor type substrate 1; SHP substrate 1; SHPS-1; Brain Ig-like molecule with tyrosine-based activation motifs (Bit); CD172 antigen-like family member A; Inhibitory receptor SHPS-1; Macrophage fusion receptor; MyD-1 antigen; BIT; MFR; MYD1; PTPNS1; SHPS1; SIRP; SIRPA
Location Membrane
Accession P78324
Clone Number S-4039
Antibody Type Mouse mAb
Isotype IgG2a,k
Application FCM
Reactivity Hu
Positive Sample human peripheral blood leukocytes
Purification Protein A
Concentration 2 mg/ml
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS pH7.4

Stability & Storage

12 months from date of receipt / reconstitution, 2 to 8 °C as supplied

Dilution


application dilution species
FCM 1:200 Hu

Background

Signal-regulatory protein alpha (SIRPα, also known as CD172a or SHPS-1) is a type I transmembrane glycoprotein of the immunoglobulin superfamily, prominently expressed on myeloid cells, neurons, and stem cells, that functions as an inhibitory receptor by binding to the broadly expressed ligand CD47 (the “don’t eat me” signal) to negatively regulate innate immune effector functions such as macrophage phagocytosis of healthy host cells; upon CD47 engagement, phosphorylation of its cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) recruits phosphatases like SHP-1 and SHP-2, thereby blocking actin cytoskeleton remodeling required for phagocytic activity, while structural studies have revealed its extracellular region contains three Ig-like domains (one V-set and two C1-set) and the interaction surface resembles antigen-receptor binding; in cancer, tumor cells exploit this CD47-SIRPα axis as an innate immune checkpoint to evade phagocytosis, making SIRPα a promising therapeutic target, especially in combination with anti-PD-1/PD-L1 therapies .

Picture

FC

Flow cytometric analysis of human peripheral blood leukocytes labelling Human CD172a (SIRPα) antibody at 1/200 (1 μg) dilution/ (right panel) compared with a Mouse IgG2a, κ Isotype Control / (left panel). Goat Anti-Mouse IgG Alexa Fluor® 488 was used as the secondary antibody.